EUROASPIRE V: adherence to cardiovascular medications


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Non-adherence to cardiovascular medication ranges from 0 per cent to 31 per cent across the 12 countries participating in the EUROASPIRE V collaborative study.

The latest findings from EUROASPIRE V relate to a sub-sample of 3,408 participants (76% male, mean age 64 years) admitted to hospital 6-24 months earlier with acute coronary syndrome (ACS), recruited from 12 countries. Patients were asked about their adherence to anti-hypertensives, hypoglycaemics and lipid-lowering therapies.

Overall, non-adherence was self-rated at 9 per cent; 7 per cent for hypoglycaemics, 7 per cent for lipid-lowering drugs and 5 per cent for anti-hypertensives. Rates varied significantly between countries, ranging from 0 per cent in the Netherlands to 31 per cent in Ukraine.

Higher education was associated with less non-adherence (9% high vs. 14% low) as was higher income (7% high vs. 14% low).

Non-adherence was highest in patients taking one class of drug (14%) compared with those on two (8%) or three (9%) and was increased in those who did not attend cardiac rehabilitation (13% attenders vs. 5% non-attenders: P<.001>

The authors say the findings support the important role of cardiac rehabilitation in treatment adherence.